- Home
- MUFG vs NVS Comparison
MUFG vs NVS Comparison
Compare MUFG & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUFG | NVS |
|---|---|---|
| Founded | 1880 | 1895 |
| Country | Japan | Switzerland |
| Employees | 178953 | 75267 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.0B | 286.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MUFG | NVS |
|---|---|---|
| Price | $20.16 | $153.37 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $144.00 |
| AVG Volume (30 Days) | ★ 3.2M | 1.7M |
| Earning Date | 05-15-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.32% | 2.16% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.62 | $2.30 |
| Revenue Next Year | $10.12 | $5.27 |
| P/E Ratio | $25.47 | ★ $23.13 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.20 | $112.34 |
| 52 Week High | $21.18 | $170.46 |
Technical Indicators
Market Signals| Indicator | MUFG | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 57.31 | 56.42 |
| Support Level | $19.57 | $149.49 |
| Resistance Level | $20.19 | $154.57 |
| Average True Range (ATR) | 0.32 | 2.25 |
| MACD | 0.03 | 0.19 |
| Stochastic Oscillator | 43.02 | 85.62 |
Price Performance
Historical ComparisonAbout MUFG Mitsubishi UFJ Financial Group Inc.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.